X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SPARC’s phenobarbital sodium powder for injection is a benzyl alcohol and propylene glycol-free formulation intended for the treatment of seizures in neonates.
Lead Product(s): Phenobarbital Sodium
Therapeutic Area: Neurology Product Name: Phenobarbital Sodium-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: $10.0 million
Deal Type: Licensing Agreement November 09, 2022
Details:
Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg.
Lead Product(s): Levetiracetam
Therapeutic Area: Neurology Product Name: Elepsia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tripoint Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 22, 2020
Details:
Sun Pharma has been granted a worldwide licence for the development and commercialization of SCD-044, which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.
Lead Product(s): SCD-044
Therapeutic Area: Dermatology Product Name: SCD-044
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: $145.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement May 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
